- Products and Services
- Educational Resources
by PierianDx, on March 18, 2020
Sequencing technology advances, such as comprehensive profiling assays, lower costs, and improved reimbursement continue to drive the adoption of clinical next generation sequencing. Organizations, such as Foundation Medicine, provide comprehensive NGS tests and resulting reports that physicians can order for patients with solid tumors. However, an increasing number of academic medical centers and healthcare organizations are opting to internalize their NGS testing program because it gives them greater control over tissue, turnaround time, and it provides more opportunity for interaction between ordering physicians and those running the tests.
Arriving at the decision to build an internal NGS test menu is often the first hurdle for healthcare organizations. What comes next can be even more challenging.
Rakesh Nagarajan, MD, PhD, Founder and Executive Chairman PierianDx, recently sat down with Joseph Anderson, MD, The Personalized Diagnostics Podcast, to discuss the advent of personalized medicine and what it will take to make clinical NGS a routine part of healthcare. In particular, Rakesh and Joe discuss:
To learn more, listen to the podcast.Read Story
by PierianDx, on March 20, 2019
PierianDx will be highlighting germline features of its genomics technology platform at the American College of Medical Genetics and Genomics (ACMG) annual meeting April 2-6 in Seattle, Washington.Read Story
by PierianDx, on February 26, 2019
Genomic tests that use next generation sequencing (NGS) technology are on the rise, and there’s a growing trend for hospitals to insource these tests to improve turnaround time and reduce costs. However, these tests can be challenging to implement. Challenges include lack of bioinformatics expertise, the cost and expense of deploying a new test, and reimbursement, to name a few.Read Story
by PierianDx, on February 25, 2019
In just under 15 years, next generation sequencing (NGS) has evolved from a technology that only an exclusive few research laboratories had access to, to one in use by nearly 300 clinical laboratories worldwide.1,2Read Story
by PierianDx, on February 7, 2019
At PierianDx, we are well-versed in helping healthcare organizations implement clinical next generation sequencing (NGS) testing programs. But beyond implementation of genomic testing programs at individual institutions, what must happen to make this technology more readily available to all?Read Story
by PierianDx, on October 24, 2018
Precision medicine is the ability to use genomic information to optimize diagnosis and treatment and provide better outcomes for patients. “We Know Precision Medicine” is a series of blog posts and articles about the people of PierianDx and how we know precision medicine through our expertise and personal experiences. In honor of breast cancer awareness month, Bryce Daines, VP Product Development, discusses his role at PierianDx and why, as the spouse of a breast cancer survivor, precision medicine is so important to him.Read Story
by PierianDx, on September 28, 2018
Join us October 31- November 3 at the Association for Molecular Pathology (AMP) annual meeting in San Antonio, Texas. Visit us any day of the conference in Booth 800. Also, plan to attend one of our workshops or in-booth presentations.
Supporting NGS-Based IVD Assays with the Most Accurate, Comprehensive and Clinically Robust Knowledgebase
Clinical NGS has been widely adopted as Laboratory Derived Tests (LDTs). NGS-based in vitro diagnostics (IVD) recently gained FDA approval with many others now in process. These IVD assays facilitate broad, widespread adoption of NGS-based testing globally in cancer and other complex conditions that require timely, accurate diagnoses and treatment. To support comprehensive interpretation of these assays, we have developed the PierianDx KnowledgeBase. Driven by the richest set of curated and rationalized content of medical interpretations, clinical practice guidelines, FDA therapeutics and clinical trials, the PierianDx KnowledgeBase offers the most well-vetted interpretations and classifications of genomic variants for IVD use.
October 31 @ 3:00 PM in RM 214D (Refreshments provided).
Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Broader adoption of next-generation sequencing-based cancer testing reveals the challenges associated with variant interpretation and underscores the need to standardize results across molecular pathology labs. In this informative workshop, we review the guidelines developed by the Association for Molecular Pathology (AMP) and describe how to put them into practice using real clinical cases.
October 31 @ 12:00 PM in RM 214D (boxed lunches provided for the first 50 to arrive).
by PierianDx, on September 13, 2018
Precision medicine is the ability to use genomic information to optimize diagnosis and treatment and provide better outcomes for patients. We Know Precision Medicine is a series of blog posts and articles about the people of PierianDx and how we know precision medicine through our expertise and personal experiences. In honor of childhood cancer awareness month, Lisa Owen, Marketing Director, discusses her role at PierianDx and why precision medicine is so important to her.Read Story
by Michael L. Sanderson, on September 4, 2018
In many healthcare settings the important role of pathology is underestimated and misunderstood. Likely, we can thank TV crime shows for the public perception that pathologists only perform autopsies and complicated analyses that help catch bad guys.Read Story
by PierianDx, on August 29, 2018
Are you considering offering clinical NGS testing or looking for an economical approach to building your program?Read Story
by PierianDx, on August 24, 2018
We Know Precision Medicine is a series of blog posts and articles about the people of PierianDx and how we know precision medicine through our expertise and personal experiences. In this article, Shalini Verma, Laboratory and Medical Director, discusses her role at PierianDx and how our products and services will help make precision medicine a routine component of healthcare.Read Story
by PierianDx, on August 14, 2018
Recently we hosted a webinar in which Medical Director, Shalini Verma, and VP Product, Andy Bredemeyer, reviewed and applied the Association for Molecular Pathology (AMP) joint consensus guidelines for the interpretation and reporting of sequence variants in cancer.Read Story